Engineering kidney tissues for polycystic kidney disease modeling and drug discovery.

Methods Cell Biol

IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy. Electronic address:

Published: May 2020

Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent, potentially lethal monogenic human disorder. There is currently no cure for ADPKD. The mechanistic complexity of the disease, the absence of animal models that can faithfully mimic the disease, as well as the lack of functional human in vitro assays for compound testing, have made drug discovery for PKD very difficult. We recently developed an engineering platform that allowed us to generate polycystic tubules using patients' own cells to test drug efficacy and discover potential new pharmacological treatments for PKD. Here we describe an engineering platform that enables the generation of custom-made polycystic tubules using patients' own cells for modeling PKD and testing drug efficacy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.mcb.2019.04.011DOI Listing

Publication Analysis

Top Keywords

polycystic kidney
8
kidney disease
8
drug discovery
8
testing drug
8
engineering platform
8
polycystic tubules
8
tubules patients'
8
patients' cells
8
drug efficacy
8
engineering kidney
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!